GlassScriptPhysician profile
Jonathan Mazurek
NPI 1902057326
$12,716.20
in general payments reported to CMS, 2019-2025
39 companies · $2,785 in 2025
The $2,785 reported for 2025 was more than what 86% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,386 · 2020: $917 · 2021: $992 · 2022: $1,637 · 2023: $2,330 · 2024: $2,669 · 2025: $2,785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,725 · Education: $59.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,724.62 |
| Education | $59.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,074.57 | 2019-2025 | |
| Janssen Biotech, INC. | $1,359.18 | 2019-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $1,213.13 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,009.69 | 2019-2024 | Xifaxan, Trulance |
| Madrigal Pharmaceuticals | $662.90 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Scientific Affairs, LLC | $559.60 | 2019-2025 | Tremfya, Stelara |
| Ardelyx, INC. | $558.50 | 2023-2025 | Ibsrela |
| Lilly USA, LLC | $511.40 | 2023-2025 | Omvoh |
| Celgene Corporation | $476.60 | 2021-2024 | Zeposia |
| Boston Scientific Corporation | $413.79 | 2019-2023 | Exalt Model D |
| Aimmune Therapeutics, INC. | $271.86 | 2023-2025 | Zenpep, Vowst |
| Gilead Sciences, INC. | $255.38 | 2019-2024 | |
| Redhill Biopharma INC. | $216.13 | 2021-2023 | Talicia, Movantik, Aemcolo |
| Intercept Pharmaceuticals, INC. | $215.14 | 2019-2025 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $172.57 | 2019-2020 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $162.92 | 2024-2025 | Voquezna |
| Pfizer INC. | $152.29 | 2023-2025 | |
| Vivus LLC | $128.03 | 2021-2025 | Pancreaze |
| Braintree Laboratories, INC. | $123.95 | 2020-2025 | Suflave, Sutab |
| Novo Nordisk INC | $117.08 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Ferring Pharmaceuticals INC. | $97.84 | 2024 | Rebyota |
| Regeneron Healthcare Solutions, INC. | $97.79 | 2024 | Dupixent |
| Allergan, INC. | $90.75 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $88.55 | 2021-2023 | |
| Celltrion USA INC. | $75.98 | 2024-2025 | Vegzelma |
| Shire North American Group INC | $73.85 | 2019 | |
| Qol Medical, LLC | $69.23 | 2022 | |
| Genzyme Corporation | $65.92 | 2022-2024 | |
| Mallinckrodt Hospital Products INC. | $61.86 | 2023-2024 | Terlivaz |
| Amgen INC. | $58.89 | 2025 | Uplizna |
| Biocon Biologics INC | $56.01 | 2025 | Yesintek, Hulio |
| Evoke Pharma, INC. | $49.15 | 2023 | Gimoti |
| Ipsen Biopharmaceuticals, INC | $48.33 | 2024-2025 | Iqirvo |
| Organon LLC | $28.36 | 2024 | |
| Alfasigma USA, INC. | $28.18 | 2020 | |
| Exact Sciences Corporation | $19.13 | 2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $18.86 | 2024 | Dificid |
| Cepheid | $16.77 | 2025 | |
| Capsovision, INC. | $16.04 | 2025 | Capsocam Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Mazurek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.